2022
Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis
Povero D, Tameda M, Eguchi A, Ren W, Kim J, Myers R, Goodman Z, Harrison S, Sanyal A, Bosch J, Ohno-Machado L, Feldstein A. Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. Scientific Reports 2022, 12: 3027. PMID: 35194091, PMCID: PMC8863778, DOI: 10.1038/s41598-022-06809-0.Peer-Reviewed Original ResearchConceptsSmall non-coding RNAsExtracellular vesiclesNon-coding RNAsNovel miRNAsControl subjectsFurther molecular characterizationMiRNA sequence analysisLiver-specific markersProtein profilingMiRNA cargoMolecular characterizationHuman diseasesCurrent serum markersNovel surrogate biomarkersPrimary sclerosing cholangitisCholestatic liver diseaseHealthy control subjectsMiRNA profilesProteinCell specificityDifferential centrifugationMiRNAsPSC patientsSclerosing cholangitisLiver disease
2019
Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis
Povero D, Pinatel E, Leszczynska A, Goyal N, Nishio T, Kim J, Kneiber D, de Araujo Horcel L, Eguchi A, Ordonez P, Kisseleva T, Feldstein A. Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight 2019, 5 PMID: 31184999, PMCID: PMC6675559, DOI: 10.1172/jci.insight.125652.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisCell MovementCell ProliferationChemical and Drug Induced Liver InjuryChemotaxisDisease Models, AnimalExtracellular VesiclesHepatic Stellate CellsHumansInduced Pluripotent Stem CellsLiverLiver CirrhosisMaleMiceMice, Inbred C57BLMicroRNAsTranscriptomeTransforming Growth Factor betaConceptsHepatic stellate cell activationChronic liver diseaseAnti-fibrotic effectsStellate cell activationLiver fibrosisLiver diseaseExtracellular vesiclesInduced pluripotent stem cellsCell activationDuct ligation-induced liver fibrosisFlow cytometryAnti-fibrotic approachesDevelopment of cirrhosisPro-fibrogenic responseProgression of fibrosisStem cell-derived extracellular vesiclesAnti-fibrotic strategiesCharacterization of iPSCsGreatest unmet needCell-derived extracellular vesiclesMiR-92a-3pWound healing responseStem cellsIPSC-EVsLiver injury
2015
Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study
Shatzel J, Dulai P, Harbin D, Cheung H, Reid T, Kim J, James S, Khine H, Batman S, Whyman J, Dickson R, Ornstein D. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single‐center retrospective cohort study. Journal Of Thrombosis And Haemostasis 2015, 13: 1245-1253. PMID: 25955079, PMCID: PMC6658183, DOI: 10.1111/jth.13000.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedAnticoagulantsDrug Administration ScheduleFemaleGastrointestinal HemorrhageHeparin, Low-Molecular-WeightHospitalizationHumansLength of StayLiver CirrhosisMaleMiddle AgedNew HampshireOdds RatioRetrospective StudiesRisk FactorsTertiary Care CentersTime FactorsTreatment OutcomeVenous ThromboembolismConceptsLow molecular weight heparinHospital bleeding eventsRetrospective cohort studyMolecular weight heparinVTE prophylaxisVenous thromboembolismBleeding eventsPharmacological thromboprophylaxisCirrhotic patientsCohort studyUnfractionated heparinWeight heparinSingle-center retrospective cohort studyEnd-stage liver disease (MELD) scoreAcademic tertiary care referral centerRate of VTETertiary care referral centerRisk of VTEGastrointestinal bleeding eventsHospitalized cirrhotic patientsNew VTE eventsPharmacological VTE prophylaxisLiver Disease scoreHospital bleedingVTE events